Abstract Number: 1312 • ACR Convergence 2023
Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry
Background/Purpose: This study aimed to identify risk factors associated with adverse events (AEs) and infections in patients with rheumatoid arthritis (RA) and comorbid interstitial lung…Abstract Number: 1734 • ACR Convergence 2023
Serum PDGF-BB Levels Correlate with Lung Fibrosis in Mice Injected with Malondialdehyde-Acetaldehyde and/or Citrulline Modified Vimentin
Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA), such as interstitial lung disease (RA-ILD), are a major contributor to morbidity and mortality. The mechanism of pulmonary…Abstract Number: 2172 • ACR Convergence 2023
Subcutaneus vs Intravenous Abatacept in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 509 Patients
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in RA-ILD. Clinical trials have shown…Abstract Number: 0307 • ACR Convergence 2023
Long-term Prognosis and Recurrence in anti-MDA-5 Antibody-positive Dermatomyositis
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is frequently complicated by rapidly progressive interstitial lung disease (ILD) and is life-threatening especially in the…Abstract Number: 0652 • ACR Convergence 2023
Ethnic Variations in Systemic Sclerosis Associated Interstitial Lung Disease
Background/Purpose: Systemic sclerosis (SSc) is a multisystem fibrosing autoimmune disease with a high mortality rate. Ethnicity can influence prevalence and disease characteristics in SSc. Less…Abstract Number: 1034 • ACR Convergence 2023
The Relationship Between the Extent of Ground Glass to Fibrosis Ratio and Treatment Response to Immunomodulatory Therapy in Three Separate Autoimmune Interstitial Lung Disease Cohorts
Background/Purpose: For patients with autoimmune interstitial lung disease (ILD), the clinician's interpretation of the extent of ground glass relative to fibrosis on imaging often influences…Abstract Number: 1319 • ACR Convergence 2023
Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients
Background/Purpose: Interstitial lung disease (ILD) is a critical complication of rheumatoid arthritis (RA). Abatacept and rituximab are the preferred disease-modifying antirheumatic drugs (DMARDs) for RA-ILD.…Abstract Number: 1764 • ACR Convergence 2023
Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) causes significant complications and mortality in patients with rheumatoid arthritis (RA). We have previously shown that patients with RA-ILD had…Abstract Number: 2173 • ACR Convergence 2023
Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in the treatment of RA-ILD, especially if…Abstract Number: 0350 • ACR Convergence 2023
Presentation, Management, and Outcomes of Systemic JIA-Associated Lung Disease: A Single Center Experience
Background/Purpose: Interstitial lung disease (ILD) is a rare and severe complication of systemic juvenile idiopathic arthritis (SJIA) that was recognized relatively recently, and its incidence…Abstract Number: 0656 • ACR Convergence 2023
Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression
Background/Purpose: Interstitial Lung Disease (ILD) in systemic sclerosis (SSc) is a common complication that has varied progression rate and prognosis. Different progression definitions include minimal…Abstract Number: 1042 • ACR Convergence 2023
B-line of Lung Ultrasound Reflects Different Morphological Features on Chest HRCT Between Interstitial Lung Disease Associated with Systemic Sclerosis and Myositis
Background/Purpose: Lung ultrasound (LUS) is a non-invasive imaging tool to evaluate distribution and severity of interstitial lung disease (ILD). Utility of LUS has been examined…Abstract Number: 1322 • ACR Convergence 2023
Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
Background/Purpose: Efzofitimod, a novel immunomodulator, has shown clinical proof-of-concept in a Phase 1b/2a clinical trial in patients with pulmonary sarcoidosis and is currently enrolling a…Abstract Number: 1771 • ACR Convergence 2023
Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Background/Purpose: Periostin is an extracellular matrix protein that contributes to the development and repair of lung tissue [1]. Previous works have described periostin as a…Abstract Number: 2174 • ACR Convergence 2023
JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and Rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 39
- Next Page »